Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:47 pm Sale | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 758,786 1.800% | -1,861,759 (-71.04%) | Filing History |
| 2024-11-14 12:04 pm Unchanged | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | Menora Mivtachim Holdings Ltd | 2,303,031 5.470% | 0 (Unchanged) | Filing History |
| 2024-11-14 08:37 am Unchanged | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | COWEN AND COMPANY, LLC | 1,796,589 4.300% | 0 (Unchanged) | Filing History |
| 2024-11-14 06:44 am Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | RTW Investments, LP | 4,930,204 9.990% | 3,203,396 (+185.51%) | Filing History |
| 2024-11-12 09:30 am Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | Adage Capital Management, L.P. | 3,735,741 8.870% | 3,735,741 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 2,497,943 5.900% | 0 (Unchanged) | Filing |
| 2024-11-06 1:50 pm Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | MORGAN STANLEY MS | 2,172,327 5.200% | 2,172,327 (New Position) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 2,497,943 5.900% | 828,400 (+49.62%) | Filing |
| 2024-06-24 5:25 pm Purchase | 2024-06-19 | 13G | UroGen Pharma Ltd. URGN | COWEN AND COMPANY, LLC | 1,796,589 4.360% | 1,796,589 (New Position) | Filing History |
| 2024-06-24 4:51 pm Purchase | 2024-06-14 | 13G | UroGen Pharma Ltd. URGN | Point72 Asset Management, L.P. | 2,569,826 6.200% | 2,569,826 (New Position) | Filing History |
| 2024-05-08 2:22 pm Sale | 2024-04-30 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 1,669,543 4.600% | -49,761 (-2.89%) | Filing |
| 2024-02-22 09:23 am Unchanged | 2023-07-28 | 13D | UroGen Pharma Ltd. URGN | Moshe Arkin | 1,369,315 4.440% | 0 (Unchanged) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 3,083,558 9.990% | 8 (+0.00%) | Filing History |
| 2024-02-14 4:38 pm Unchanged | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 2,620,545 8.490% | 0 (Unchanged) | Filing History |
| 2024-02-14 10:02 am Sale | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | Menora Mivtachim Holdings Ltd | 2,303,031 7.460% | -615,971 (-21.10%) | Filing History |
| 2024-02-14 10:01 am Sale | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | Stonepine Capital Management, LLC | 0 0.000% | -1,304,947 (Position Closed) | Filing History |
| 2024-02-14 07:07 am Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | RTW Investments, LP | 1,726,808 5.600% | 1,726,808 (New Position) | Filing History |
| 2024-02-02 2:18 pm Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 1,719,304 5.600% | 1,378,892 (+405.07%) | Filing |
| 2023-12-29 4:30 pm Purchase | 2023-12-19 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 3,083,550 9.990% | 3,083,550 (New Position) | Filing History |
| 2023-09-15 1:39 pm Purchase | 2023-09-08 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 2,620,545 8.510% | 2,620,545 (New Position) | Filing History |